Vincerx Pharma, Inc. Common Stock (VINC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) has a cash flow conversion efficiency ratio of -2.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($2.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Vincerx Pharma, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Vincerx Pharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vincerx Pharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vincerx Pharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Siam Cement Public Company Limited
F:TCM1
|
0.018x |
|
OVATION SCIENCE I
F:0VH
|
N/A |
|
Seed Innovations Ltd
LSE:SEED
|
-0.032x |
|
Proteome Sciences PLC
LSE:PRM
|
-0.089x |
|
Amur Minerals Corporation
LSE:CRTX
|
-0.663x |
|
Mercantile Ports & Logistics Ltd
LSE:MPL
|
-0.010x |
|
VELA TECHNOL.PLC LS-0001
F:IBNN
|
N/A |
|
ULTRA BRANDS LTD.
F:X6T
|
0.000x |
Annual Cash Flow Conversion Efficiency for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Vincerx Pharma, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.72 Million | $-26.13 Million | -9.591x | -166.07% |
| 2023-12-31 | $11.22 Million | $-40.45 Million | -3.605x | -188.29% |
| 2022-12-31 | $47.67 Million | $-59.60 Million | -1.250x | -275.55% |
| 2021-12-31 | $100.32 Million | $-33.40 Million | -0.333x | -742.78% |
| 2020-12-31 | $57.69 Million | $-2.28 Million | -0.040x | -104.85% |
| 2019-12-31 | $-43.00K | $-35.00K | 0.814x | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more